PLoS ONE (Jan 2023)

Liver function indicators in patients with breast cancer before and after detection of hepatic metastases-a retrospective study.

  • Carmen Leser,
  • Georg Dorffner,
  • Maximilian Marhold,
  • Anemone Rutter,
  • Mert Döger,
  • Christian Singer,
  • Deirdre Maria König-Castillo,
  • Christine Deutschmann,
  • Iris Holzer,
  • Daniel König-Castillo,
  • Daphne Gschwantler-Kaulich

DOI
https://doi.org/10.1371/journal.pone.0278454
Journal volume & issue
Vol. 18, no. 3
p. e0278454

Abstract

Read online

BackgroundLiver metastases are common in patients with breast cancer, and determining the factors associated with such metastases may improve both their early detection and treatment. Given that liver function protein level changes in these patients have not been determined, the aim of our study was to investigate liver function protein level changes over time, spanning 6 months before the detection of liver metastasis to 12 months after.MethodsWe retrospectively studied 104 patients with hepatic metastasis from breast cancer who were treated at the Departments of Internal Medicine I and the Department of Obstetrics and Gynecology at the Medical University of Vienna between 1980 and 2019. Data were extracted from patient records.ResultsAspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, lactate dehydrogenase and alkaline phosphatase were significantly elevated when compared to normal range 6 months before the detection of liver metastases (pConclusionLiver function protein levels should be considered as potential indicators when screening for liver metastasis in patients with breast cancer. With the new treatment options available, it could lead to prolonged life.